Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

Por Orrell, Catherine, Felizarta, Franco, Nell, André, Kakuda, Thomas N., Lavreys, Ludo, Nijs, Steven, Tambuyzer, Lotke, Van Solingen-Ristea, Rodica, Tomaka, Frank L.
Publicado no AIDS Res Treat (2015)

Pharmacokinetic Interaction between Telaprevir and Methadone

Por van Heeswijk, Rolf, Verboven, Peter, Vandevoorde, Ann, Vinck, Petra, Snoeys, Jan, Boogaerts, Griet, De Paepe, Els, Van Solingen-Ristea, Rodica, Witek, James, Garg, Varun
Publicado em 2013

884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies

Por Teichner, Paula, Cutrell, Amy, D’Amico, Ronald, Dorey, David, Griffith, Sandy, Harrington, Conn M, Huang, Jenny, Hudson, Krischan J, Margolis, David, Mrus, Joseph, Polli, Joseph, Spreen, William, Williams, Peter, Van Solingen-Ristea, Rodica, Shaefer, Mark S
Publicado no Open Forum Infect Dis (2019)

1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies

Por Teichner, Paula, Wu, Sterling, Zhang, Feifan, Dorey, David, D’Amico, Ronald, Griffith, Sandy, Sutton, Kenneth, McCoig, Cynthia C, Upadhyay, Ojesh R, Polli, Joseph, Margolis, David, Van Solingen-Ristea, Rodica, Vandermeulen, Kati, Spreen, William, Patel, Parul
Publicado no Open Forum Infect Dis (2020)

638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results

Por Smith, Graham, Henry, Keith, Podzamczer, Daniel, Masiá, Mar, Bettacchi, Christopher, Arasteh, Keikawus, Jaeger, Hans, Khuong-Josses, Marie-Aude, Sutton, Kenneth, Zhang, Feifan, McCoig, Cynthia C, Vandermeulen, Kati, Van Solingen-Ristea, Rodica, Spreen, William, Margolis, David
Publicado no Open Forum Infect Dis (2020)

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Por Rizzardini, Giuliano, Overton, Edgar T., Orkin, Chloe, Swindells, Susan, Arasteh, Keikawus, Górgolas Hernández-Mora, Miguel, Pokrovsky, Vadim, Girard, Pierre-Marie, Oka, Shinichi, Andrade-Villanueva, Jaime F., Richmond, Gary J., Baumgarten, Axel, Masiá, Mar, Latiff, Gulam, Griffith, Sandy, Harrington, Conn M., Hudson, Krischan J., St. Clair, Marty, Talarico, Christine L., Patel, Parul, Cutrell, Amy, Van Eygen, Veerle, D'Amico, Ronald, Mrus, Joseph M., Wu, Sterling, Ford, Susan L., Chow, Ken, Roberts, Jeremy, Wills, Angela, Walters, Nicola, Vanveggel, Simon, Van Solingen-Ristea, Rodica, Crauwels, Herta, Smith, Kimberly Y., Spreen, William R., Margolis, David A.
Publicado no J Acquir Immune Defic Syndr (2020)